Navigation Links
Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
Date:11/6/2008

er cancer patients has been initiated that will test immediate post operative (IPOP) intravesical administration of Chemophase, the combination of rHuPH20 with mitomycin C immediately following transurethral resection of bladder tumor (TURBT). Results of this small safety study will be used to support the inclusion of the IPOP dosing regimen as part of the protocol in future Chemophase studies. Halozyme is making preparations to meet with regulatory authorities during the first half of 2009 to discuss the trial design for potential registration studies.

-- Halozyme hosted its first Research Day for financial analysts and the investment community on October 6, 2008 in New York. The well attended event provided a forum for an in depth presentation and discussion by the Halozyme management team of its proprietary product development pipeline, its plans for future clinical trials, and its business strategy. A replay of the meeting can be found on the Halozyme website. (http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-calendar)

-- The company has recently strengthened its senior management team with the addition of Douglas B. Muchmore, M.D., Vice President, Endocrinology Clinical Development, Patrick O'Connor, Ph.D., Vice President, Research, Michael J. LaBarre, Ph.D., Vice President, Product Development, and James E. Cartoni, Vice President, Legal. Successfully recruiting, developing, and retaining high caliber, experienced executives exemplifies Halozyme's commitment to exceptional talent.

-- Positive pre-clinical animal efficacy data (http://www.halozyme.com/2008AACRTCsk-4%20-%20large.pdf)were presented for PEGPH20 at the American Association for Cancer Research (AACR) Translational Cancer Medicine meeting in Monterey, Calif. on July 21, 2008. The study demonstrat
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
2. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics to Host Research Day for Investors and Analysts
5. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
8. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
9. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Sigma-Aldrich Corporation (NASDAQ: ... under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) ... 22, 2014, thereby completing the U.S. HSR Act ... of the Company by Merck KGaA, Darmstadt, Germany.  ... condition to closing the transaction, which remains subject ...
(Date:12/22/2014)... Brussels (PRWEB) December 22, 2014 The ... the global leader of technical training across the life ... Clinical Data Management (SCDM) to provide the organization's ... certification programs —providing access to the more than 350 ... SCDM members with 10% off when registering for a ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy ... that it has signed a letter of intent ... has developed and patented a nanotechnology-based development platform ... products that enable rapid on-site collection and testing ... and health issues in an immediate, non-invasive and ...
(Date:12/22/2014)... December 22, 2014 The ... publication of original research, reviews and editorials addressing ... clinical practice, today published a provocative article exploring ... development, progression and potential treatment of prostate cancer. ... research and proposes the possibility that there could ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... 26, 2011 Mylan Inc. (Nasdaq: MYL ) today ... September 30, 2011. Financial Highlights ... 30 compared to $0.43 for the same prior year period; ... September 30 compared to $1.16 for the same prior year period; ...
... Calif., Oct. 25, 2011 Life Technologies Corporation ... Dx Genetic Analyzer has been approved by China,s State Food ... Dx is a capillary-based Sanger Sequencer intended for use in ... of genetic changes that may lead to disease presence or ...
... MENLO PARK, Calif. and IPSWICH, Mass., Oct. 25, 2011 ... of products and services for studying regulatory elements in ... New England Biolabs, Inc. (NEB) to create a new ... of SwitchGear,s LightSwitch™ Luciferase Assay System and NEB,s BioLux® ...
Cached Biology Technology:Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 2Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 3Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 4Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 5Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 6Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 7Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 8Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 9Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 10Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 11Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 12Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 13Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 14Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 15Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 16Life Technologies Launches 3500 Dx Series Genetic Analyzers for In Vitro Diagnostic Use in China 2Life Technologies Launches 3500 Dx Series Genetic Analyzers for In Vitro Diagnostic Use in China 3Life Technologies Launches 3500 Dx Series Genetic Analyzers for In Vitro Diagnostic Use in China 4SwitchGear Genomics and New England Biolabs Develop New Multiplex Reporter Assay System 2
(Date:12/5/2014)... Dec. 4, 2014  Tute Genomics, a leader in ... in Series A1 funding led by UK-based Eurovestech. Peak ... in the investment round. "We are at ... adopts next-generation sequencing and seeks new approaches for the ... Robison , MD MBA, and CEO of Tute Genomics. ...
(Date:11/21/2014)... 18, 2014 According to a ... Systems (Video, RFID, Access Control, Intrusion Detection, Parking Management, ... Government), Component Service Geography - Global Forecasts to 2020", ... projected to be around $25 Billion in 2014 and ... at a CAGR of 8.69%. Browse 116 ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014   Atmel® ... leader in microcontroller (MCU) and touch technology solutions, today ... temperature sensors with the widest V cc ... higher temperature accuracy and faster I 2 C bus ... and serial EEPROM memory making them ideal for consumer, ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... This news release is available in French . ... with today,s technology, it still takes both a male and a female ... raise that child? Many studies have outlined the value of a mother, ... New findings from the Research Institute of the McGill University Health Centre ...
... Dangerous Climate Change: Required Reductions of Carbon Emissions to ... Hansen and colleagues, and announces call for papers on ... assesses climate impacts of global warming using ongoing observations ... and simple representations of the global carbon cycle and ...
... Nov. 27, 2013 The mating roar of a male ... predator. Unfortunately for the seals, scientists have found evidence that ... present their work at the 166th Meeting of the Acoustical ... San Francisco, Calif. Previous research had shown mammal-eating killer ...
Cached Biology News:Dads: How important are they? 2Assessing dangerous climate change and call for climate change response papers 2Silent stalkers of dark ocean waters 2
A Highly Purified, Cost-Effective Taq DNA Polymerase...
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
... SUPERaseIn RNase Inhibitor (patent pending) is a ... noncovalently binds and inhibits the most common ... C, 1 and T1. SUPERaseIn can be ... could be problematic. It is ideal for ...
... (Chemical Inkjet Printer) is a revolutionary ... and Protein Macroarray Analysis, developed in ... The strategy compliments established protocols in ... the proteins isoelectric point and apparent ...
Biology Products: